PGHL2024-04-012024-06-30 PGHL2024-04-012024-06-30 PGHL2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member PGHL2024-04-012024-06-30in-bse-fin:FourOperatingExpenses01Member PGHL2024-06-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 500126 PGHL NOTLISTED Procter & Gamble Health Limited Equity 2023-07-01 2024-06-30 2024-08-21 2024-06-27 INR Lakhs Yearly 12:00:00 15:50:00 2024-08-21 2024-08-21 true Cash Flow Indirect Declaration of unmodified opinion Single segment PHARMACEUTICALS 2024-04-01 2024-06-30 Audited Standalone 2838800000.00 21300000.00 2860100000.00 674200000.00 185100000.00 -67600000.00 486300000.00 2000000.00 71600000.00 1078300000.00 2429900000.00 430200000.00 -201900000.00 228300000.00 127900000.00 -67400000.00 60500000.00 0.00 167800000.00 0.00 0.00 0.00 0.00 167800000.00 -10100000.00 157700000.00 0.00 0.00 166000000.00 10 10.11 10.11 0.00 0.00 10.11 10.11 0.00 0.00 0.00 1. The above audited financial results for the quarter and year ended June 30, 2024 have been reviewed and recommended by the Audit Committee, and approved by the Board of Directors of the Company at their Meeting held on August 21, 2024. The statutory auditors have issued an unmodified audit report thereon. 2. Results for all above period have been prepared in accordance with Indian Accounting Standards ( Ind AS ) as prescribed under section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standard) Rules, 2015, as amended. 3. The figures of last quarter are the balancing figures between audited figures in respect of full year and published year to date figures upto the third quarter of financial year. 4. The Board of Directors at its meeting held on August 21, 2024 has recommended for the current year final dividend off 60 per equity share (nominal value off 10 per equity share) aggregating to~ 9 9S9 lakhs subject to approval of members at the ensuing Annual General Meeting of the Company. 5. During the Quarter, certain employees opted for the Company's existing voluntary retirement scheme. Employee cost includes expense amounting to f 144 lakhs (for the previous quarter ended 31st March 2024 expense off 259 lakhs & for the year ended 30th June 2024 expense off 3 002 lakhs) in this regard. 6. During the financial year, the Company discontinued production of injections at its manufacturing plant in Goa effective September 30, 2023, as the Company started to source injections portfolio of its products from a contract manufacturer. Post evaluation of various alternatives, during the quarter the Company has entered into an agreement for sale of the assets of its injection plant for a consideration of~ 790 Lakhs and impaired the balance amount off 627 Lakhs. Based on above, the company has re-evaluated the usability of assets in their capital work in progress and thereby impaired other related assets by an amount off 1392 Lakhs. The above total amount on 2 019 Lakhs have been disclosed as an exceptional item for the quarter and the year ended June 30, 2024. 7. The Company has identified Pharmaceuticals as its single primary reportable segment in accordance with the requirement of Ind AS 108 - Operating Segments. Accordingly no separate segment information has been provided. 8. Previous periods figures have been regrouped/ reclassified wherever necessary. Single segment 2023-07-01 2024-06-30 Audited Standalone 11512600000.00 156300000.00 11668900000.00 2902300000.00 394600000.00 8700000.00 2151600000.00 7200000.00 274000000.00 2995400000.00 8733800000.00 2935100000.00 -201900000.00 2733200000.00 809400000.00 -86000000.00 723400000.00 0.00 2009800000.00 0.00 0.00 0.00 0.00 2009800000.00 6700000.00 2016500000.00 0.00 0.00 166000000.00 10 5216400000.00 121.07 121.07 0.00 0.00 121.07 121.07 0.00 0.00 0.00 Other Expenses 1078300000.00 Other Expenses 2995400000.00 1256400000.00 58900000.00 19000000.00 0.00 9600000.00 0.00 0.00 0.00 0.00 0.00 97400000.00 904300000.00 1001700000.00 336900000.00 18900000.00 2701400000.00 1091100000.00 0.00 853300000.00 2385000000.00 58600000.00 17200000.00 133700000.00 3447800000.00 0.00 613300000.00 5152200000.00 90000000.00 0.00 7943600000.00 166000000.00 5216400000.00 5382400000.00 5382400000.00 0.00 0.00 68800000.00 68800000.00 296400000.00 0.00 6900000.00 372100000.00 0.00 1670000000.00 256900000.00 1926900000.00 125300000.00 102400000.00 34500000.00 0.00 2189100000.00 2561200000.00 7943600000.00 7200000.00 231300000.00 291700000.00 0.00 0.00 0.00 0.00 182700000.00 0.00 -716100000.00 0.00 -110800000.00 0.00 481000000.00 0.00 -11400000.00 0.00 0.00 0.00 20200000.00 0.00 -117300000.00 6900000.00 0.00 0.00 -21000000.00 0.00 -77500000.00 0.00 401500000.00 3134700000.00 0.00 0.00 0.00 851900000.00 0.00 2282800000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1400000.00 217300000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 126200000.00 0.00 21000000.00 0.00 -68700000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 31100000.00 4149900000.00 0.00 0.00 0.00 -4181000000.00 -1966900000.00 0.00 -1966900000.00 4354200000.00 2387300000.00 -13400000.00 9000000.00 -3300000.00 2300000.00 0.00 0.00